Skip to content

Preferred Stock at other companies

LQD
Liquidia CorporationLQDA
$0
Revvity logo
RevvityRVTY
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$0
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$0
ALN
Alnylam PharmaceuticalsALNY
$0

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Ligand Pharmaceuticals's preferred stock?
Ligand Pharmaceuticals (LGND) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.